US-based biotechnology company Moderna’s Covid-19 vaccine demonstrated 94.1 per cent efficacy, showed results from the primary analysis of a phase-3 trial.
The study, published in The New England Journal of Medicine, provides evidence that the vaccine, mRNA-1273, can prevent symptomatic infection.
The results are similar to the first interim analysis of the study announced by Moderna in November which showed vaccine efficacy of 94.5 per cent. The new paper published on Wednesday said that among the more than 30,000 participants randomised to receive the vaccine or a placebo, 11 of those in the vaccine group developed symptomatic Covid-19 compared to 185 participants who received the placebo, demonstrating 94.1 per cent efficacy in preventing symptomatic COVID-19.